| Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors AS Kanate, A Mussetti, MA Kharfan-Dabaja, KW Ahn, A DiGilio, ... Blood, The Journal of the American Society of Hematology 127 (7), 938-947, 2016 | 288 | 2016 |
| Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma G Iacoboni, G Villacampa, N Martinez‐Cibrian, R Bailén, L Lopez Corral, ... Cancer Medicine 10 (10), 3214-3223, 2021 | 85 | 2021 |
| Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure SM Smith, J Godfrey, KW Ahn, A DiGilio, S Ahmed, V Agrawal, ... Cancer 124 (12), 2541-2551, 2018 | 75 | 2018 |
| Reduced-intensity allografting as first transplantation approach in relapsed/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors E Klyuchnikov, U Bacher, NM Kröger, PN Hari, KW Ahn, J Carreras, ... Biology of Blood and Marrow Transplantation 21 (12), 2091-2099, 2015 | 61 | 2015 |
| Effective treatment of pomalidomide in central nervous system myelomatosis A Mussetti, S Dalto, V Montefusco Leukemia & lymphoma 54 (4), 864-866, 2013 | 60 | 2013 |
| Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide–based haploidentical versus matched sibling donor reduced-intensity conditioning transplant … S Ahmed, JA Kanakry, KW Ahn, C Litovich, H Abdel-Azim, M Aljurf, ... Biology of blood and marrow transplantation 25 (9), 1859-1868, 2019 | 59 | 2019 |
| Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma M Kwon, G Iacoboni, JL Reguera, LL Corral, RH Morales, ... Haematologica 108 (1), 110, 2023 | 54 | 2023 |
| Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa C Gudiol, A Albasanz-Puig, J Laporte-Amargós, N Pallarès, A Mussetti, ... Antimicrobial agents and chemotherapy 64 (4), 10.1128/aac. 02494-19, 2020 | 52 | 2020 |
| Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study É Azoulay, P Castro, A Maamar, V Metaxa, AG De Moraes, L Voigt, ... The Lancet Haematology 8 (5), e355-e364, 2021 | 51 | 2021 |
| Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand? A Mussetti, R Greco, J Peccatori, P Corradini Expert review of hematology 10 (5), 479-492, 2017 | 49 | 2017 |
| Extracorporeal photopheresis for treatment of acute and chronic graft versus host disease: an Italian multicentric retrospective analysis on 94 patients on behalf of the Gruppo … M Malagola, V Cancelli, C Skert, PF Leali, E Ferrari, A Tiburzi, ML Sala, ... Transplantation 100 (12), e147-e155, 2016 | 49 | 2016 |
| Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia MJ Wieduwilt, L Metheny III, MJ Zhang, HL Wang, N Estrada-Merly, ... Blood advances 6 (1), 339-357, 2022 | 47 | 2022 |
| Impact of pretransplantation 18f-fluorodeoxy glucose–positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma V Bachanova, LJ Burns, KW Ahn, GG Laport, G Akpek, ... Biology of Blood and Marrow Transplantation 21 (9), 1605-1611, 2015 | 42 | 2015 |
| Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma E Klyuchnikov, U Bacher, K Woo Ahn, J Carreras, NM Kröger, PN Hari, ... Bone marrow transplantation 51 (1), 58-66, 2016 | 38 | 2016 |
| Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell … V Montefusco, F Spina, F Patriarca, M Offidani, B Bruno, M Montanari, ... Biology of Blood and Marrow Transplantation 19 (3), 424-428, 2013 | 35 | 2013 |
| Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors MR Grunwald, MJ Zhang, H Elmariah, MH Johnson, A St. Martin, ... Blood Advances 5 (4), 975-983, 2021 | 29 | 2021 |
| Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post-transplantation cyclophosphamide graft-versus-host disease prophylaxis L Castagna, A Mussetti, R Devillier, A Dominietto, M Marcatti, G Milone, ... Biology of Blood and Marrow Transplantation 23 (9), 1549-1554, 2017 | 28 | 2017 |
| Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide V Montefusco, M Galli, F Spina, P Stefanoni, A Mussetti, G Perrone, ... Leukemia & lymphoma 55 (9), 2032-2037, 2014 | 27 | 2014 |
| Handling the COVID-19 pandemic in the oncological setting A Mussetti, C Maluquer, A Albasanz-Puig, C Gudiol, G Moreno-Gonzalez, ... The Lancet Haematology 7 (5), e365-e366, 2020 | 26 | 2020 |
| CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide A Mussetti, C De Philippis, C Carniti, M Bastos-Oreiro, J Gayoso, N Cieri, ... Bone Marrow Transplantation 53 (12), 1522-1531, 2018 | 25 | 2018 |
